Clinical trial
Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
NCT01618370 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- Lead sponsor
- Bayer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 22, 2012
- Completion date
- February 28, 2016
- Enrollment
- 705 (actual)
- Sites
- 215
Conditions
As the registry lists them; a condition with its own page is linked.